Tiziana Life Sciences (TLSA) said Thursday it does not intend to embark on any capital raising activity "for the immediate future."
The company said the decision comes after the news that came out on Wednesday about the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis treated with nasal foralumab.
Tiziana said it continues to be committed to delivering shareholder value and advancing its drug candidates via clinical trials and regulatory processes.
Tiziana shares fell 10% in recent trading.
Price: 0.72, Change: -0.08, Percent Change: -10.01
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。